Pharma BD Deal Intelligence

Novartis AG / Voyager Therapeutics Inc.

2024 · Licensing/Option · $1.3B · Complete

Announcement Sentiment

75

Strongly positive

Outcome Score

60

Largely worked — most objectives met.

Novartis paid $100M upfront for access to Voyager's gene therapy programs targeting Huntington's disease and spinal muscular atrophy.

Key facts

Announced Jan 02, 2024
Closed Jan 02, 2024
Deal value $1.3B
Deal type Licensing/Option
Therapeutic area Gene Therapy, Neurology, Rare Disease
Indications Huntington's disease, Spinal muscular atrophy
Key assets Gene therapy candidates
Mechanism AAV gene therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals